BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema

Outcome of Brolucizumab-dbll and Aflibercept Intravitreal Injection in the Treatment of Diabetic Macular Edema

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04955171

Enrollment

Registered

2021-07-08

Start date

2021-01-12

Completion date

2022-04-30

Last updated

2021-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Edema

Keywords

BEOVU, Eylea, diabetic macular edema

Brief summary

Diabetic macular edema degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management

Detailed description

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab(BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea;Regeneron, Tarrytown,NY)

Interventions

DRUGBEOVU intravitreal injection

BEOVU intravitreal injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diabetic macular edema

Exclusion criteria

* other causes of macular edema * other macular diseases

Design outcomes

Primary

Measure	Time frame	Description
Best corrected visual acuity (BCVA)	12 months	Change in BCVA in LOG MARS(logarithm minimum angle of resolution

Countries

United Arab Emirates

Contacts

Primary ContactTAREK R ELHAMAKY, MD

thamaky@ibnnafees.com+9712 443 8999

Backup ContactTAREK ELHAMAKY